Secondary prevention effectiveness in patients with stable angina
Abstract
Aim. To assess the effectiveness of pharmaceutical secondary prevention in ambulatory patients with stable angina (SA), in the real-worl clinical settings. Material and methods. Retrospective analysis of randomly selected ambulatory medical histories (n=1067; year 2006) of SA patients attending Bishkek centres of family medicine. Results. The main groups of anti-anginal medications (AAM), prescribed by primary healthcare doctors, were beta-adrenoblockers (BAB; 43,0 %), nitrates (28,6 %), and calcium antagonists (CA; 27,9 %). Anti-aggregants were prescirbed to 86,8 % of the patients, and ACE inhibitors — to 82,2 %. Myocardial cytoprotectors were prescribed less often (0,5 %), as well as lipid-lowering agents (8,4 %). The prescribed doses of lipid-lowering agents were inadequately low (minimal effective doses). Generic lipid-lowering medications were prescrbed more often (93,3 %) than the original ones (6,7 %). Conclusion. Pharmaceutical secondary prevention in SA patients was not adequate and did not comply with the modern clinical guidelines.
About the Authors
Rasim Kutlu
Kyrgyz Sate Medical Academy
Russian Federation
Russian Federation
T. M. Murataliev
Kyrgyz Sate Medical Academy;
Academician Mirsaid Mirrakhimov National Centre of Cardiology and Therapy. Bishkek
Kyrgyzstan
Kyrgyzstan
References
1. Здоровье населения и деятельность учреждений здравоохранения Кыргызской Республики. Бишкек 2000; 152 с.
2. Здоровье населения и деятельность учреждений здравоохранения Кыргызской Республики. Бишкек 2006; 275 с.
3. Информационный центр ВОЗ по здоровою население и здравоохранение в Центрально-азиатских республиках, Health of population and health care in central Asian republics WHO information center on health for. Carinfonet J 2000; 1: 3-15.
4. EUROASPIRE Study Group EUROASPIRE European Society of Cardiology survey of secondary prevention of coronary heart disease. Principal results. Eur Heart J 1999; 18: 1569-82.
5. EUROASPIRE II Study Group Life style and risk factor management and use of drag therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programmer. Eur Heart J 2001; 22: 554-72.
6. Euro Heart Survey Programme ESC Quality Assurance Programme to Improve Cardiac Care in Europe. Euroaspire III Euro Heart Survey on Secondary and Primary Prevention Of Coronary Heart Disease. Euro Heart Survey ESC Сongress, Vienna, september 2007.
7. Eastaugh JL, Calvert MJ, Freemantle N, et al. Highlighting the need for better patient care instable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patients Family Practice. Eur Heart J 2004; 21: 1-8.
8. Witold R, Caroline AD, Anselm G, et al. Prospective observational study from the Euro heart survey of stable angina: Predicting prognosis instable angina—results. BMJ J 2006; 332: 262-7.
9. Strom BL. What is pharmacoepidemiology? 2nd еd. New York. John Wiley & Sons, Inc. J 1994; 6: 3-15.
10. Комитет экспертов ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации. Кардиоваск тер профил 2008г. http://familymedicine.ru/content/ view/246/32/
11. Kim F, Maria A, Diego A, et al. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 10: 1001-93.
12. Theodore D, Fraker J, Stephan D, et al. A Report of the American 2007 Chronic Angina Focused Updated of the ACC/ AHA 2002 Guidelines for the for the Management of Patients With Chronic Stable Angina. Circulation J 2007; 116: 1-12.
Review
For citations:
Kutlu R., Murataliev T.M. Secondary prevention effectiveness in patients with stable angina. Cardiovascular Therapy and Prevention. 2010;9(4):45-48. (In Russ.)
Views:
776
Email this article 
